CLINICAL_TRIALS
trial_result
· 2020-09-16
Clinical Trial Update: Pegcetacoplan (APL-2) in Neovascular AMD [Phase 1, Phase 2]
Summary
Phase 1/2 trial of pegcetacoplan (APL-2) in neovascular age-related macular degeneration was terminated; results posted in 2020.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Apellis Pharmaceuticals, Inc. | Conditions: Neovascular Age-related Macular Degeneration | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-09-16